10th June, 2020, 08:30 – 09:00 CET

Lung cancer is responsible for 1 in 5 cancer deaths in Europe. Last year, around half a million Europeans were diagnosed with lung cancer and 400,000 people died of the disease. The survival rates are quite low, but thanks to improvements in diagnosis, surgery, radiotherapy and medicines, they are getting better. The question is, should we screen more aggressively for lung cancer now, or not?.

23rd of October 13.00-14.00 Eastern US

This webinar presents original research by Vital Transformation that will be peer review published in Therapeutic Innovation and Regulatory Science, showing the devastating impact on R&D, Investments, and patients that will be caused by reference pricing in the United States.

With the increasing use of new regulatory tools, like the FDA’s breakthrough therapy designation, there are increasing demands for European health technology assessors (HTAs) to make an accurate assessment of the long-term value and performance of CAR-T therapies from smaller datasets and shorter outcomes. This webinar will highlight our recent publication in the BMJ, sponsored by ZIN, which showcases a novel approach to harnessing RWE and develops a longitudinal data set that can be used for effectiveness measures, even in orphan conditions. As well, we will kickoff our new research project in Diffuse large B-cell lymphoma (DLBCL) and describe how we will leverage our methodology to measure the effectiveness of the various options for treatment, both in emerging CAR-T treatments, as well as existing chemotherapy regimes and bone-marrow transplants.